drugset

drugset / Trial / NCT03512275

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

NCT03512275 ↗

Phase 2 Completed 42 enrolled Janssen Research & Development, LLC

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.

Timeline

Start: 2018-06-20
Primary completion: 2019-01-14
Completion: 2019-01-14

Publications

Gottlieb A, Natsis NE, Kerdel F, Forman S, Gonzalez E, Jimenez G, Hernandez L, Kaffenberger J, Guido G, Lucas K, Montes D, Gold M, Babcock C, Simard J. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain. J Invest Dermatol. 2020 Aug;140(8):1538-1545.e2. doi: 10.1016/j.jid.2019.10.024. Epub 2020 Jan 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bermekimab	Monoclonal antibody	400 mg	Subcutaneous

Indications